Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal fluid retention describes the abnormal accumulation or failed absorption of fluid within the intestine. It is a broad pathophysiological concept rather than a molecular or protein target. Intestinal fluid balance is tightly regulated by coordinated absorption and secretion by enterocytes, mainly determined by transport proteins such as sodium/hydrogen exchangers (NHEs), epithelial sodium channels (ENaC), and chloride channels (e.g., CFTR). Dysregulation, e.g., during inflammation, heart failure, liver cirrhosis, or specific transporter mutations, leads to symptoms such as diarrhea or edema. Many drugs (e.g., diuretics, oral rehydration solutions, NHE3 inhibitors like tenapanor) act by targeting specific molecular transporters to modulate fluid transport, but 'intestinal fluid retention' itself is not a direct drug target. Clinical diseases related to this process include edema, ascites, and various diarrheal or malabsorptive disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal fluid retention.